The Danish pharmaceutical giant Novo Nordisk – one of Europe's highest-valued listed companies – licked its wounds after the price slump that wiped out 21 percent of the stock exchange's value on Friday.
In Monday's trading on the Copenhagen Stock Exchange, the share recovered and rose by 5.7 percent.
Friday's price crash, which pushed down the Danish krone and spread great concern among Danish savers and investors, came after a study showed that Novo Nordisk's new weight-loss drug Cagrisema did not meet expectations.
With Monday's recovery, Novo Nordisk's share is now down 10.7 percent since the beginning of 2024.
